Stocks-ALNY-Alnylam Pharmaceuticals Inc

ALNY Alnylam Pharmaceuticals Inc

214.73 2.02 (0.95%)
in USD Market Open
Invest
Invest

Overview

Prev Close212.72
Day's Range 211.09 - 216.38
52 Week Range 117.27 - 236.22
Average Volume (3m)968.62K
1-Year Return18.92%
Beta0.7121
Market Cap26.17B
P/E Ratio
Revenue960.92M
EPS-9.7715
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.716/06/202229/08/202208/11/2022125.00150.00175.00200.00225.00250.00
Chart times in UTC
Industry Pharmaceuticals Major
CEO Yvonne L. Greenstreet, MD, MBA
Employees 1,665

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: Alnylam Pharmaceuticals Inc's revenues increased by 71.31% and amounted to 844.29M. Net income increased by 0.64% to -852.82M. Net assets decreased by 42.12% to 588.20M and EPS increased from -7.46 to -7.20.
ALNY's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
83.85%
Net Profit Margin
-448.18%
Operating Margin
-82.32%
Return On Investment
-40.27%
12/21
03/22
06/22
09/22
Total Revenue
258.54M
213.26M
224.82M
264.31M
Gross Profit
220.87M
177.63M
184.01M
223.19M
Operating Income
-194.56M
-146.73M
-191.69M
-258.04M
Net Income
-258.46M
-240.34M
-277.4M
-405.92M